Verastem Inc (FRA:2VSA)
€ 4.06 0.24 (6.28%) Market Cap: 193.89 Mil Enterprise Value: 145.66 Mil PE Ratio: 0 PB Ratio: 16.62 GF Score: 35/100

Verastem Inc at H C Wainwright BioConnect Conference (Virtual) Transcript

Jan 11, 2021 / NTS GMT
Release Date Price: €24.46 (+8.35%)
Sean Lee
H.C. Wainwright & Co, LLC, Research Division - Equity Research Associate

Good afternoon, everyone, and thank you for joining the H.C. Wainwright 2021 BioConnect Conference. My name is Sean Lee, and I'm an equity research analyst at the firm. While we are virtual this year, we are confident we are going to be able to provide value to you with over 375 companies presenting at this conference.

Today, I am hosting a fireside chat with the CEO of Verastem Oncology, Mr. Brian Stuglik. Brian, to start with off and for the benefit of the investors who aren't -- may not be familiar with Verastem, could you give us some background on the company and its product pipeline?

Brian Stuglik
Verastem, Inc. - CEO & Director

Sure. Thank you, Sean, and thank you to H.C. Wainwright for hosting the virtual conference. So Verastem is a Boston-based company. We were founded in 2010, and we're as a research-based organization. In 2020, we went through a pretty significant transformation of the company. Beginning in January of 2020, we in-licensed what we now

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot